Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyHighmark Pennsylvania NDC Submission Requirement |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHighmark PennsylvaniaPolicy N/A

    Highmark List of Procedure Codes Requiring NDC

    Customize your policy alerts

    Sign up for all Highmark Pennsylvania policy alerts

    Know when Highmark Pennsylvania releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    A Highmark Pennsylvania reimbursement/policy list identifying HCPCS/CPT procedure codes that require submission of an NDC (National Drug Code) effective 07/01/2024; applies to providers billing Highmark Pennsylvania for the listed injectable/oral drug administrations.

    Policy Summary
    PayerHighmark Pennsylvania
    PolicyHighmark List of Procedure Codes Requiring NDC
    Policy CodePolicy N/A
    Change TypeInformational — new billing requirement
    Effective DateJul 1, 2024
    Next Review DateN/A
    Key ActionProviders must submit the National Drug Code (NDC) on claims for the listed HCPCS/HCPCS J/Q procedure codes when billing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    07/01/2024Requirement effective
    ~320Approx. codes listed
    yesIncludes unclassified codes
    multipleTherapeutic classes

    Procedure Codes Requiring NDC — Coverage Criteria

    inv-01: Codes requiring NDC (partial list)

    The following HCPCS / J-codes require submission of the corresponding National Drug Code (NDC) on the claim when billed to Highmark Pennsylvania (partial list).

    When billing any of the HCPCS/J codes listed below, the claim must include the corresponding NDC to identify the drug product.

    Examples (partial)

    • 90378 — RESPIRATORY SYNCYTIAL VIRUS, MONOCLONAL ANTIBODY, RECOMBINANT, FOR INTRAMUSCULAR USE, 50 MG, EACH
    • C9399 — UNCLASSIFIED DRUGS OR BIOLOGICALS
    • J0121 — INJECTION, OMADACYCLINE, 1 MG
    • J0456 — INJECTION, AZITHROMYCIN, 500 MG

    Code Lists and Examples

    Sample codes from list (partial)mixed
    90378RESPIRATORY SYNCYTIAL VIRUS, MONOCLONAL ANTIBODY, RECOMBINANT, FOR INTRAMUSCULAR USE, 50 MG, EACH
    C9399UNCLASSIFIED DRUGS OR BIOLOGICALS
    J0121INJECTION, OMADACYCLINE, 1 MG
    Sample J-codes requiring NDCHCPCS
    J1571INJECTION, HEPATITIS B IMMUNE GLOBULIN HEPAGAM B, INTRAMUSCULAR, 0.5 ML
    J1595INJECTION, GLATIRAMER ACETATE, 20 MG
    J1745INJECTION, INFLIXIMAB, 10 MG
    Example HCPCS/J codes requiring NDCHCPCS
    J7294WILLEBRAND FACTOR COMPLEX, RECOMBINANT (ALTUVIIIO), PER FACTOR VIII A.U.
    J7295ETHINYL ESTRADIOL AND ETONOGESTREL, 0.015MG, 0.12MG PER 24 HOURS; MONTHLY VAGINAL RING, EACH
    J7300INTRAUTERINE COPPER CONTRACEPTIVE
    Antineoplastic/oncology J-codes requiring NDCHCPCS
    J9000DOXORUBICIN HCL, 10 MG
    J9022INJECTION, ATEZOLIZUMAB, 10 MG
    J9264PACLITAXEL PROTEIN-BOUND PARTICLES, 1 MG
    Selected J-codes requiring NDCHCPCS
    J9354MARGETUXIMAB-CMKB, 5 MG
    J9355ADO-TRASTUZUMAB EMTANSINE, 1 MG
    J9356TRASTUZUMAB, EXCLUDES BIOSIMILAR, 10 MG
    J9395FULVESTRANT, 25 MG
    J9400ZIV-AFLIBERCEPT, 1 MG
    Selected biosimilar Q-codes requiring NDCHCPCS
    Q5101FILGRASTIM-SNDZ (biosimilar)
    Q5112TRASTUZUMAB-DTTB (biosimilar)
    Q5124RANIBIZUMAB-NUNA (biosimilar)
    Q5131ADALIMUMAB-AACF (biosimilar)
    Selected S-codes and other HCPC entriesHCPCS
    S5550INSULIN, RAPID ONSET; 5 UNITS
    S0013ESKETAMINE, NASAL SPRAY, 1 MG
    S0104ZIODVUDINE, ORAL, 100 MG

    Billing Requirements and Actions for Providers

    Billing Rule

    NDC Submission Requirement — Listed Procedure/HCPCS/J Codes

    Providers must submit the National Drug Code (NDC) when billing any of the procedure/HCPCS/J codes listed below. Failure to report the NDC may result in claim processing delays or denial. This requirement is effective 07/01/2024.

    • Effective 07/01/2024: Submit NDC on all claims for the listed procedure/HCPCS/J codes.
    • Include product NDC, unit of measure, and number of units consistent with the billed code and dosing.
    Billing Rule

    NDC Requirement for Listed Procedure Codes

    Providers must report the NDC for the following HCPCS/J procedure codes when submitting claims. The Highmark List of Procedure Codes Requiring NDC (effective 07/01/2024) includes, but is not limited to, the codes shown across this policy. Always reference the full Highmark code list when preparing claims.

    Definitions and Notes

    National Drug Code (NDC) submission requirement
    NDC submission requirementThe payer requires submission of the corresponding National Drug Code (NDC) on claims when billing the procedure/HCPCS codes listed in this document (effective 07/01/2024)
    Effective dateRequirement effective 07/01/2024
    Potential claim impactClaims without required NDC information may be subject to rejection or denial
    Unclassified drug/biologic — NDC reporting
    Unclassified codes includedUnclassified drug/biologic codes such as J3490 and J3590 are included in the list and require NDC reporting when used
    Specific unclassified entryJ3591 is listed as 'UNCLASSIFIED DRUG OR BIOLOGICAL USED FOR ESRD ON DIALYSIS' and requires NDC
    Policy Summary
    PayerHighmark Pennsylvania
    PolicyHighmark List of Procedure Codes Requiring NDC
    Policy CodePolicy N/A
    Change TypeInformational — new billing requirement
    Effective DateJul 1, 2024
    Next Review DateN/A
    Key ActionProviders must submit the National Drug Code (NDC) on claims for the listed HCPCS/HCPCS J/Q procedure codes when billing.
    SourceLink
    On This Page
    Procedure Codes Requiring NDC — Coverage CriteriaCode Lists and ExamplesBilling Requirements and Actions for ProvidersDefinitions and Notes
    J0457 — INJECTION, AZTREONAM, 100 MG

    inv-02: NDC submission requirement

    When submitting claims for the HCPCS/J procedure codes listed below, the claim must include the corresponding NDC.

    NDC submission is required on claims for the listed HCPCS/J procedure codes; omission of the NDC may result in claim rejection or denial.

    Selected codes (partial)

    • J1571 — INJECTION, HEPATITIS B IMMUNE GLOBULIN (HEPAGAM B), INTRAMUSCULAR, 0.5 ML
    • J1595 — INJECTION, GLATIRAMER ACETATE, 20 MG
    • J1745 — INJECTION, INFLIXIMAB, 10 MG
    • J1602 — INJECTION, GOLIMUMAB, 1 MG, FOR INTRAVENOUS USE

    inv-03: NDC submission requirement (billing rule)

    Billing rule: for the specific HCPCS/Q/J codes shown, providers must report the product NDC on the claim.

    When billing any HCPCS/Q/J code listed in Highmark's procedure code list, submit the corresponding NDC on the claim to identify the drug/biologic product.

    Example entries (partial)

    • J7294 — WILLEBRAND FACTOR COMPLEX, RECOMBINANT (ALTUVIIIO), PER FACTOR VIII A.U.
    • J9306 — INJECTION, PERTUZUMAB, 1 MG
    • J9310 — INJECTION, RITUXIMAB, 100 MG
    • J9395 — INJECTION, FULVESTRANT, 25 MG
    • Q0138 — INJECTION, FERUMOXYTOL, FOR TREATMENT OF IRON DEFICIENCY ANEMIA, 1 MG (NON-ESRD USE)

    inv-04: Product-specific eligibility snippets

    Product-specific eligibility notes where provided in the list.

    Q0220 / Q0221 — Tixagevimab and cilgavimab are listed for pre‑exposure prophylaxis; when billing these codes include the NDC. See age/weight eligibility below.
    Age and weight requirement — applies to Q0220/Q0221: patient must be 12 years of age or older AND weigh at least 40 kg.

    Operational note: ensure NDC is reported on the claim for these prophylaxis products in addition to confirming patient age and weight eligibility as specified.

    Unclassified drug/biologic codes requiring NDC
    Included unclassified codesJ3490, J3590, J3591 are included in the list and therefore require submission of an NDC when billed
    C9399 referenceC9399 is listed as 'UNCLASSIFIED DRUGS OR BIOLOGICALS' and captured in the NDC requirement list
    Scope of inclusionUnclassified codes are treated the same as other HCPCS/J-codes for NDC reporting on claims
    Age and weight eligibility for Q0220/Q0221
    Age requirement for Q0220/Q0221Patients must be 12 years of age or older
    Weight requirement for Q0220/Q0221Patients must weigh at least 40 kg
    Indication contextQ0220/Q0221 are listed for pre-exposure prophylaxis for certain adults and pediatric individuals meeting the age/weight criteria
  1. Examples of included codes (partial list): 90378, C9399, J0121, J0122, J0129, J0130, J0135, J0153, J0172, J0177, J1571, J1572, J1595, J1602, J1627, J7294, J9354, J9355, J9356, J9358, J9360, J9370, J9371, J9380, J9381, J9390, J9395, J9400, J9600, J9999, Q0138, Q0139, Q0166, Q0167, Q0180
  2. Providers should consult the complete Highmark list in this policy for all codes requiring NDC submission.
  3. Billing Rule

    COVID-19 Monoclonal Antibody and Prophylaxis NDC Requirement

    For COVID-19 monoclonal antibodies and COVID-19 prophylaxis agents, providers must submit the NDC for the listed Q-codes and related HCPCS drug codes when billing. This includes pre-exposure prophylaxis agents and COVID-19 monoclonal antibody treatments — submit the NDC to ensure correct benefit/administration adjudication.

    • COVID-19 related codes requiring NDC (examples): Q0220, Q0221, Q0222, Q0224, Q0239 (and any other COVID-19 monoclonal antibody or prophylaxis HCPCS/Q-codes on the Highmark list).
    • These requirements apply to agents used for pre-exposure prophylaxis and monoclonal antibody treatment; include the specific product NDC and dosage for each billed unit.
    • Effective date: 07/01/2024 — submit NDC information on all claims for these COVID-19 related codes.
    Treatment parityUnclassified codes are captured alongside specific J-/Q-/S-codes for NDC submission purposes
    Procedure codes requiring NDC (definition)
    DefinitionThe listed procedure/HCPCS codes are those for which an NDC must be submitted on the claim as of the stated effective date
    List coverageIncludes J-codes, Q-codes, S-codes and other HCPCS identifiers enumerated in the document
    Use on claimsProviders must supply the corresponding NDC for the specific drug product administered when billing any code on the list
    HCPCS J-codes — correspondence to specific drug products
    HCPCS/J-code meaningHCPCS J-codes listed correspond to specific drug products or formulations (for example, injections, oral chemotherapeutics, inhalation solutions)
    ExamplesEntries include inhalation solutions (J7674), oral chemotherapy agents (J8510, J8520) and injectable biologics (multiple J9xxx entries)
    Coding implicationEach J-code maps to a particular drug/product description that must be identified by NDC on the claim
    Pre-exposure prophylaxis — term note
    Term definitionPre-exposure prophylaxis (as used here) refers to administration of agents (e.g., tixagevimab and cilgavimab, Q0220/Q0221) to prevent SARS‑CoV‑2 infection in eligible individuals prior to exposure
    Target population noteUsed for individuals who are moderately to severely immunocompromised or who cannot receive COVID‑19 vaccination due to severe adverse reaction
    Associated codesPre-exposure prophylaxis agents in the list include Q0220, Q0221, Q0224 and related Q-codes
    Biosimilar HCPCS/Q-codes — term note
    Biosimilar Q-code meaningBiosimilar HCPCS/Q-codes in the list identify biosimilar versions of reference biologics (e.g., Q5112 trastuzumab-dttb, Q5124 ranibizumab-nuna)
    Examples presentDocument includes multiple biosimilar entries such as Q5108 (bevacizumab-aWWB), Q5112, Q5113 and others
    NDC reporting requirementBiosimilar Q-code entries are subject to the same NDC submission requirement as other listed codes